Skip to main content

Table 2 Secondary outcome measures

From: Evaluation of the mechanisms of sarcopenia in chronic inflammatory disease: protocol for a prospective cohort study

CLD IBD RA
• Change in model for end-stage liver disease (MELD) scores over the 24-week period.
• Complications of CLD (frequency of ascitic paracentesis, number of hospital admissions, the incidence of serious infections such a spontaneous bacterial peritonitis).
• For those who undergo LT, post-operative complications, e.g. length of admission.
• Transplant free survival time.
• Quality of life measures.
• Physical activity indices.
• Change in clinical status.
• Change in mucosal healing, as defined by Travis et al, [45], symptoms scoring including Harvey Bradshaw Index scoring and severity staging including Mayo scoring.
• Complications of IBD (number of hospital admissions, number of acute flares).
• Quality of Life measures.
• Physical activity indices.
• Change in disease activity (ACR response criteria, DAS28 response, achievement of ACR/EULAR remission criteria).
• Complications of RA (number of hospital admissions, number of acute flares)
• Quality of life measures.
• Physical activity indices.